This was derived from an individual carrying a quadruple wild-type (KRAS, NRAS, BRAF and PIK3CA) colorectal tumour, and thus recapitulates the molecular profile of patients sensitive to anti-EGFR antibodies. This evidence concerns the gene PIK3CA and colorectal neoplasm.